Biopharma Shakti Initiative

Context

Recently, the Union Finance Minister announced the launch of a new initiative called "Biopharma Shakti" during Budget 2026–27. It aims to empower India's biopharmaceutical sector.

About the Biopharma Shakti Initiative

• Biopharma Shakti broadly translates to "Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation."
• This initiative is designed to make India a major hub for global biopharma manufacturing.
• Under this initiative, a comprehensive and enabling ecosystem will be developed to promote domestic production of biologics and biosimilars.
• The program includes the establishment of a dedicated biopharma network, under which three new National Institutes of Pharmaceutical Education and Research (NIPERs) will be established, while seven existing institutes will be upgraded to meet modern requirements.
• Additionally, the goal is to develop a strong network of over 1,000 accredited clinical trial centers across the country.

Financial Provision and Duration

• An investment of approximately ₹10,000 crore has been allocated for this initiative over the next five years.
• This investment will focus on building advanced biomanufacturing infrastructure, promoting research and innovation, and strengthening India's capabilities in high-value and next-generation medical technologies.

Objective and Strategic Importance

The primary objective of Biopharma Shakti is to build an innovation and manufacturing network that can effectively address India's changing healthcare needs. In particular, this initiative has been developed keeping in mind the increasing burden of non-communicable diseases such as diabetes, cancer, and autoimmune diseases.

What are Biologics

• Biologics are complex drugs derived from living cells or organisms.
• Their availability has traditionally been limited due to their highly complex manufacturing process, and their use has been confined primarily to high-income countries.

What are biosimilars ?

• Biosimilars are highly similar versions of original biological drugs.
• They undergo extensive analytical studies, as well as rigorous preclinical and clinical trials, to ensure therapeutic equivalence, efficacy, and safety.
• These drugs increase market competition by providing similar therapeutic benefits, helping to reduce the cost of biological treatments.